Neurogenic orthostatic hypotension after treatment with sorafenib
Wippel C, Deshpande H, Patwa H, Peixoto A. Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 2022, 15: e247140. PMID: 36549761, PMCID: PMC9791444, DOI: 10.1136/bcr-2021-247140.Peer-Reviewed Original ResearchConceptsOrthostatic hypotensionVascular endothelial growth factor inhibitorsLower extremity weaknessNeurogenic orthostatic hypotensionPalpable abdominal massGrowth factor inhibitorsHistory of fatigueAppropriate chronotropic responseSupine hypertensionAbdominal painAutonomic testingExtremity weaknessAbdominal massSodium intakeChronotropic responseFactor inhibitorsCompression stockingsDesmoid tumorsLiberal fluidsSympathetic responseHypotensionTumor growthSorafenibGradual improvementTreatmentSevere inpatient hypertension prevalence and blood pressure response to antihypertensive treatment
Ghazi L, Li F, Chen X, Simonov M, Yamamoto Y, Biswas A, Hanna J, Shah T, Townsend R, Peixoto A, Wilson FP. Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Journal Of Clinical Hypertension 2022, 24: 339-349. PMID: 35174627, PMCID: PMC8925013, DOI: 10.1111/jch.14431.Peer-Reviewed Original ResearchConceptsSevere hypertensionBlood pressure responseBP elevationUntreated patientsCox proportional hazards modelRetrospective cohort studyPressure responseProportional hazards modelAntihypertensive treatmentInpatient hypertensionMore comorbiditiesPossible overtreatmentHospitalized adultsCohort studyHypertension prevalenceArterial pressureHospitalized patientsTreatment guidelinesHypertensionGreater rateHazards modelPatientsAntihypertensivesTreatmentAdmission